scholarly journals Total robotic pancreatoduodenectomy with pancreatico-jejunostomy by modified Blumgart technique

2021 ◽  
Vol 25 (1) ◽  
pp. S138-S138
Author(s):  
Vaibhav Kumar VARSHNEY ◽  
Sunita SUMAN
Keyword(s):  
Robotic Pancreatoduodenectomy

scholarly journals Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Kosei Takagi ◽  
Yuzo Umeda ◽  
Ryuichi Yoshida ◽  
Kazuhiro Yoshida ◽  
Kazuya Yasui ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumor ◽  
Lymph Node Metastases ◽  
Treatment Strategy ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Ki 67 ◽  
Invasive Approach ◽  
Robotic Pancreatoduodenectomy ◽  
Estimated Blood Loss ◽  
Node Metastases

Abstract Background Contrary to the increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), GEP-NETs of the accessory papilla of the duodenum are extremely rare. Furthermore, there have been no recommendations regarding the treatment strategy for GEP-NETs of the accessory papilla of the duodenum. We present a case of GEP-NET of the accessory papilla of the duodenum successfully treated with robotic pancreatoduodenectomy. Case presentation A case of a 70-year-old complaining of no symptoms was diagnosed with GEP-NET of the accessory papilla of the duodenum. A 8-mm tumor was located at the submucosal layer with a biopsy demonstrating a neuroendocrine tumor grade 1. The patient underwent robotic pancreatoduodenectomy as curative resection for the tumor. The total operative time was 406 min with an estimated blood loss of 150 mL. The histological examination revealed a well-differentiated neuroendocrine tumor with low Ki-67 index (< 1%). In the posterior areas of the pancreas, the lymph node metastases were detected. The patient was followed up for 6 months with no recurrence postoperatively. Conclusions Considering the potential risks of the lymph node metastases, the standard treatment strategy for GEP-NETs of the accessory papilla of the duodenum should be radical resection with pancreatoduodenectomy. Minimally invasive approach can be the alternative to the conventional open surgery.

Pancreas anastomosis after laparoscopic and robotic pancreatoduodenectomy

2021 ◽  
Author(s):  
Fernando Pardo Aranda ◽  
Esteban Cugat Andorrà ◽  
Manel Cremades Pérez ◽  
Alba Zárate Pinedo
Keyword(s):  
Robotic Pancreatoduodenectomy

Indications, technique, and results of robotic pancreatoduodenectomy

2016 ◽  
Vol 68 (3) ◽  
pp. 295-305 ◽  
Author(s):  
Niccolò Napoli ◽  
Emanuele F. Kauffmann ◽  
Francesca Menonna ◽  
Vittorio Grazio Perrone ◽  
Stefania Brozzetti ◽  
...  
Keyword(s):  
Robotic Pancreatoduodenectomy

Added Value of 3D-vision During Biotissue Robotic Pancreatoduodenectomy Anastomoses (LAEBOT-3D2D): a Randomized Controlled Cross-Over Trial

Pancreatology ◽  
2020 ◽  
Vol 20 ◽  
pp. S182
Author(s):  
M. Zwart ◽  
L. Jones ◽  
B. Balduzzi ◽  
K. Takagi ◽  
A. Vanlander ◽  
...  
Keyword(s):  
Added Value ◽  
3D Vision ◽  
Randomized Controlled ◽  
Robotic Pancreatoduodenectomy

Robotic pancreatoduodenectomy with vascular resection: Outcomes and learning curve

Surgery ◽  
2019 ◽  
Vol 166 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Joal D. Beane ◽  
Mazen Zenati ◽  
Ahmad Hamad ◽  
Melissa E. Hogg ◽  
Herbert J. Zeh ◽  
...  
Keyword(s):  
Learning Curve ◽  
Vascular Resection ◽  
Robotic Pancreatoduodenectomy

scholarly journals Robotic versus Open Pancreatoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL): a study protocol for a multicenter phase III non-inferiority randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jiabin Jin ◽  
Yusheng Shi ◽  
Mengmin Chen ◽  
Jianfeng Qian ◽  
Kai Qin ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Functional Recovery ◽  
High Volume ◽  
Phase Iii ◽  
Postoperative Adjuvant Chemotherapy ◽  
Randomized Controlled ◽  
Link Type ◽  
Robotic Pancreatoduodenectomy ◽  
Large Patient ◽  
Secondary Outcomes

Abstract Background Pancreatoduodenectomy is a complex and challenging procedure that requires meticulous tissue dissection and proficient suturing skills. Minimally invasive surgery with the utilization of robotic platforms has demonstrated advantages in perioperative patient outcomes in retrospective studies. The development of robotic pancreatoduodenectomy (RPD) in specific has progressed significantly, since first reported in 2003, and high-volume centers in pancreatic surgery are reporting large patient series with improved pain management and reduced length of stay. However, prospective studies to assess objectively the feasibility and safety of RPD compared to open pancreatoduodenectomy (OPD) are currently lacking. Methods/design The PORTAL trial is a multicenter randomized controlled, patient-blinded, parallel-group, phase III non-inferiority trial performed in seven high-volume centers for pancreatic and robotic surgery in China (> 20 RPD and > 100 OPD annually in each participating center). The trial is designed to enroll and randomly assign 244 patients with an indication for elective pancreatoduodenectomy for malignant periampullary and pancreatic lesions, as well as premalignant and symptomatic benign periampullary and pancreatic disease. The primary outcome is time to functional recovery postoperatively, measured in days. Secondary outcomes include postoperative morbidity and mortality, as well as perioperative costs. A sub-cohort of 128 patients with pancreatic adenocarcinoma (PDAC) will also be compared to assess the percentage of patients who undergo postoperative adjuvant chemotherapy within 8 weeks, in each arm. Secondary outcomes in this cohort will include patterns of disease recurrence, recurrence-free survival, and overall survival. Discussion The PORTAL trial is designed to assess the feasibility and safety of RPD compared to OPD, in terms of functional recovery as described previously. Additionally, this trial will explore whether RPD allows increased access to postoperative adjuvant chemotherapy, in a sub-cohort of patients with PDAC. Trial registration ClinicalTrials.govNCT04400357. Registered on May 22, 2020

Sign in / Sign up

Export Citation Format

Share Document